Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study

Benjamin A. Teply(Johns Hopkins University), Hao Wang(Johns Hopkins University), Brandon Luber(Johns Hopkins Medicine), Rana Sullivan(Johns Hopkins University), Irina Rifkind(Johns Hopkins Medicine), Ashley Bruns(Johns Hopkins Medicine), Avery Spitz(Johns Hopkins Medicine), Morgan Decarli(Johns Hopkins Medicine), Victoria J. Sinibaldi(Johns Hopkins Medicine), Caroline F. Pratz(Johns Hopkins University), Changxue Lu(Johns Hopkins Medicine), John L. Silberstein(Johns Hopkins University), Jun Luo(Johns Hopkins University), Michael T. Schweizer(University of Washington), Charles G. Drake(Johns Hopkins University), Michael A. Carducci(Johns Hopkins University), Channing J. Paller(Johns Hopkins Medicine), Emmanuel S. Antonarakis(Johns Hopkins Medicine), Mario A. Eisenberger(Johns Hopkins University), Samuel R. Denmeade(Johns Hopkins Medicine)
The Lancet Oncology
December 13, 2017
10.1016/s1470-2045(17)30906-3
Cited by 194Open Access
Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis